Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Bill Becomes Law: Industry Focuses On What Didn’t Make the Cut

This article was originally published in The Gray Sheet

Executive Summary

A Medicare bill made law last week was of interest to device firms as much or more for what it did not contain than for what it did include
Advertisement

Related Content

HHS IG Urges Medicare To Crack Down On Negative Pressure Pump Payments
CMS Weighs Changes To Competitive Bidding Program
Rule Calls For Durable Medical Equipment Competitive Rebids In 2009
Imaging Procedure Volume Grows While Price Caps Cut Medicare’s Bill – GAO
Need For Blinded Payment In Randomized Trials Is Recognized In Recent Bills
Much Research, Little Action On Comparative Effectiveness
Medicare Bill Passed By Congress Delays DMEPOS Bidding Program
Medicare Bill Passed By Congress Delays DMEPOS Bidding Program
Industry Sees Room For Better Diagnostics Payments In Medicare Package
Device Industry Looks To SCHIP Bill For Medicare Reforms
Advertisement
UsernamePublicRestriction

Register

MT026356

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel